IL17A and rheumatoid arthritis: Accordingly, several clinical trials targeting the IL-17 pathway in RA [21], psoriasis [22,23], psoriatic arthritis (PsA) [24] and ankylosing spondylitis [25] have been initiated (reviewed in [26]).